Zacks: Analysts Anticipate Ironwood Pharmaceuticals, Inc. (IRWD) Will Post Quarterly Sales of $92.91 Million

Wall Street analysts expect that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will post sales of $92.91 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Ironwood Pharmaceuticals’ earnings, with the highest sales estimate coming in at $95.81 million and the lowest estimate coming in at $88.22 million. Ironwood Pharmaceuticals posted sales of $86.83 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 7%. The company is expected to issue its next earnings report on Thursday, November 1st.

According to Zacks, analysts expect that Ironwood Pharmaceuticals will report full-year sales of $340.47 million for the current fiscal year, with estimates ranging from $327.43 million to $349.78 million. For the next year, analysts anticipate that the business will post sales of $440.96 million per share, with estimates ranging from $392.49 million to $530.18 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Monday, August 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.09). The business had revenue of $81.10 million during the quarter, compared to analyst estimates of $82.61 million. Ironwood Pharmaceuticals had a negative return on equity of 2,073.20% and a negative net margin of 34.03%. Ironwood Pharmaceuticals’s revenue was up 24.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.28) EPS.

Several brokerages have weighed in on IRWD. BidaskClub downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 26th. Zacks Investment Research downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, April 18th. Morgan Stanley reissued an “underweight” rating and issued a $13.00 price target on shares of Ironwood Pharmaceuticals in a report on Wednesday, May 9th. ValuEngine raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Finally, Barclays lifted their target price on Ironwood Pharmaceuticals from $16.00 to $20.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 2nd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $19.11.

Ironwood Pharmaceuticals traded down $0.39, hitting $18.82, during trading on Tuesday, according to MarketBeat. The company’s stock had a trading volume of 703,541 shares, compared to its average volume of 1,008,305. The company has a debt-to-equity ratio of -8.64, a quick ratio of 4.40 and a current ratio of 2.94. The company has a market cap of $2.94 billion, a PE ratio of -20.24 and a beta of 0.81. Ironwood Pharmaceuticals has a fifty-two week low of $12.89 and a fifty-two week high of $21.20.

In related news, insider Thomas A. Mccourt sold 30,000 shares of Ironwood Pharmaceuticals stock in a transaction dated Friday, July 6th. The stock was sold at an average price of $20.00, for a total transaction of $600,000.00. Following the completion of the sale, the insider now owns 30,000 shares of the company’s stock, valued at $600,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Halley E. Gilbert sold 29,551 shares of Ironwood Pharmaceuticals stock in a transaction dated Tuesday, July 3rd. The stock was sold at an average price of $19.75, for a total value of $583,632.25. Following the sale, the insider now directly owns 29,551 shares of the company’s stock, valued at approximately $583,632.25. The disclosure for this sale can be found here. Insiders have sold 61,051 shares of company stock valued at $1,210,062 in the last ninety days. Corporate insiders own 7.63% of the company’s stock.

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new position in Ironwood Pharmaceuticals in the first quarter valued at approximately $138,000. Meeder Asset Management Inc. acquired a new position in Ironwood Pharmaceuticals in the second quarter valued at approximately $186,000. Quantitative Systematic Strategies LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at approximately $180,000. A.R.T. Advisors LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the first quarter valued at approximately $208,000. Finally, V Wealth Management LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the second quarter valued at approximately $258,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Featured Article: How Do I Invest in Dividend Stocks

Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply